Impact of maternal and infant antiretroviral drug regimens on drug resistance in HIV-infected breastfeeding infants.

ABSTRACT:

Background

The HIV Prevention Trials Network (HPTN) 046 trial evaluated the efficacy of extended infant nevirapine (NVP) administration for prevention of HIV transmission through breastfeeding. Infants received daily NVP up to 6 weeks of age. HIV-uninfected infants (the intent-to-treat group) received daily NVP or placebo up to 6 months of age. We analyzed emergence of NVP resistance in infants who acquired HIV infection despite prophylaxis.

Methods

HIV genotyping was performed using the ViroSeq HIV Genotyping System. Medians and proportions were used to summarize data. Two-sided Fisher exact tests were used to evaluate associations between categorical variables.

Results

NVP resistance was detected in 12 (92.3%) of 13 infants who were HIV-infected by 6 weeks and in 7

SUBMITTER: Fogel JM 

PROVIDER: S-EPMC3826537 | biostudies-literature | 2013 Apr

REPOSITORIES: biostudies-literature